HC Wainwright & Co. Reiterates Buy on Pliant Therapeutics, Maintains $38 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has reiterated its Buy rating for Pliant Therapeutics, maintaining a price target of $38.
September 13, 2024 | 10:58 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
HC Wainwright & Co. has reiterated its Buy rating for Pliant Therapeutics, maintaining a price target of $38, indicating confidence in the company's future performance.
The reiteration of a Buy rating and maintenance of a $38 price target by a reputable analyst firm like HC Wainwright & Co. suggests positive sentiment and confidence in Pliant Therapeutics' future performance. This could lead to increased investor interest and potentially a positive impact on the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100